Trial Profile

A phase I/II study assessing Allogeneic G-NK cell therapy for cancer

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 08 Feb 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 Feb 2021 According to an Indapta Therapeutics media release, this trial is expected to begin in 2H 2021.
28 Oct 2020 According to a Multiple Myeloma Research Foundation media release, The Multiple Myeloma Research Foundation (MMRF) and Indapta Therapeutics announced a partnership to support this trial and this collaboration is supported with an investment in Indapta by the MMRF's venture philanthropy arm, the Myeloma Investment Fund (MIF).
09 Jul 2020 According to an Indapta Therapeutics media release, the company plans to initiate this study in summer 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com